Browse our anti-NEK2 (NEK2) Antibodies

Mouse (Murine) NIMA (Never in Mitosis Gene A)-Related Kinase 2 (NEK2) interaction partners

1. Cep85 is a bona fide Nek2A-binding partner that surrounds the proximal ends of centrioles where it cooperates with PP1gamma (also known as PPP1CC (show PPP1CC Antibodies)) to antagonize Nek2A

2. The results suggest that overexpression of NEK2 has the potential to serve as a biomarker for PCa (show ENPP1 Antibodies) prognosis.

3. Nek2 transgenic mice develop spontaneous germinal centers and exhibit an enhanced T cell dependent immune response our data demonstrates a novel role for Nek2 in regulating B cell development and the immune response

4. these data indicate that Nek2 has a pivotal role in breast cancer growth at primary and secondary sites, and thus may be an attractive and novel therapeutic target for this disease.

5. CIP2A (show KIAA1524 Antibodies) strongly interacts with NEK2 during G2/M phase, thereby enhancing NEK2 kinase activity to facilitate centrosome separation in a PP1 (show PPP1CC Antibodies)- and PP2A (show PPP2R2B Antibodies)-independent manner.

6. Nek2 and its substrate, centrobin/Nip2, are required for proper meiotic spindle formation of the mouse oocytes

7. Data show that NEK2 was identified as a tumor-associated antigen.

8. Nek2 may be a mitotic regulator that is involved in diverse cell cycle events.

9. Tcp10 promoter-directed expression of the Nek2 gene in mouse meiotic spermatocytes.

10. The MAPK (show MAPK1 Antibodies) pathway triggers activation of Nek2 during chromosome condensation in mouse spermatocytes.

Human NIMA (Never in Mitosis Gene A)-Related Kinase 2 (NEK2) interaction partners

1. Taken together with the result that gamma-taxilin (show TXLNG Antibodies) protein expression levels were decreased at the onset of mitosis, we propose that gamma-taxilin (show TXLNG Antibodies) participates in Nek2A-mediated centrosome disjunction as a negative regulator through its interaction with Nek2A.

2. NEK2 can promote HCC (show FAM126A Antibodies) metastasis through induction of the epithelial-mesenchymal transition.

3. evaluated the role of NEK2 in bone destruction of MM via clinical gene expression profiling data analysis and in vitro and in vivo mouse models. Further, treatment with the heparanase (show HPSE Antibodies) inhibitor Roneparstat, a Phase 1 drug in MM treatment,14 markedly inhibited OCL (show OCLN Antibodies) differentiation and rescued bone mass loss induced by NEK2 overexpression, suggesting that targeting NEK2 and/or its signaling pathway may be not only for preven

4. Nek2 is able to individually shorten cilia when cilia are growing but requires interaction with Aurora A (show AURKA Antibodies) when cilia are being absorbed. PP1 (show PPA1 Antibodies) binding protein, PPP1R42 (show PPP1R42 Antibodies), directly inhibits Nek2 and increases cilia formation.

5. Data suggest that low NIMA-related kinase 2 (NEK2) expression might be a useful predictor in hepatocellular carcinoma (HCC (show FAM126A Antibodies)) as a poor prognostic factor, and could serve as a potential therapeutic target for HCC (show FAM126A Antibodies).

6. present study firstly reveals that NEK2 protein is widely overexpressed in gliomas. NEK2 overexpression correlates significantly with malignancy (WHO grades), proliferation (Ki-67 (show MKI67 Antibodies)) and prognosis in malignant gliomas

7. Results found NEK2 to be upregulated in lung cancer tissues and, its 3'-UTR (show UTS2R Antibodies) mRNA is directly targeted by miR (show MLXIP Antibodies)-128 to regulate its protein expression.

8. Displacement of Dishevelled (DVL (show DVL2 Antibodies)) from the centrosome and its release into the cytoplasm on NEK2 phosphorylation is coupled to the removal of linker proteins.

9. NEK2 promotes aerobic glycolysis through regulating splicing of PKM and increasing the PKM2/PKM1 ratio in myeloma cells which contributes to its oncogenic activity.

10. Nek2A is found to stabilize SuFu (show SUFUH Antibodies) at least partly depending on its kinase activity, thereby triggering phosphorylation of the SuFu (show SUFUH Antibodies) protein.